Docoh
Loading...

VBIV VBI Vaccines

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Company profile

Ticker
VBIV
Exchange
CEO
Jeffrey R. Baxter
Employees
Location
Fiscal year end
Former names
LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.
SEC CIK

VBIV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Mar 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 93.83M 93.83M 93.83M 93.83M 93.83M 93.83M
Cash burn (monthly) 444.33K (positive/no burn) 5.12M 3.94M 5.5M 3.92M
Cash used (since last report) 1.61M n/a 18.52M 14.25M 19.89M 14.18M
Cash remaining 92.22M n/a 75.3M 79.57M 73.94M 79.64M
Runway (months of cash) 207.5 n/a 14.7 20.2 13.4 20.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Jan 21 Baxter Jeff Option (Right to Buy Common Shares) Common Shares Grant Aquire A No No 3.15 1,000,000 3.15M 1,000,000
27 Jan 21 Steven Gillis Option (Right to Buy Common Shares) Common Shares Grant Aquire A No No 3.15 100,000 315K 100,000
27 Jan 21 Anderson David Evander Option (Right to Buy Common Shares) Common Shares Grant Aquire A No No 3.15 500,000 1.58M 500,000
27 Jan 21 McNulty Christopher Option (Right to Buy Common Shares) Common Shares Grant Aquire A No No 3.15 500,000 1.58M 500,000
27 Jan 21 Joanne Cordeiro Option (Right to Buy Common Shares) Common Shares Grant Aquire A No No 3.15 75,000 236.25K 75,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

47.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 123 113 +8.8%
Opened positions 34 25 +36.0%
Closed positions 24 13 +84.6%
Increased positions 48 39 +23.1%
Reduced positions 25 39 -35.9%
13F shares
Current Prev Q Change
Total value 431.02M 492.59M -12.5%
Total shares 121.55M 126.18M -3.7%
Total puts 934.9K 1.32M -29.0%
Total calls 531.4K 808.4K -34.3%
Total put/call ratio 1.8 1.6 +8.0%
Largest owners
Shares Value Change
Perceptive Advisors 55.04M $151.37M 0.0%
STT State Street 22.29M $61.31M +20.1%
BLK Blackrock 13.18M $36.23M +7.8%
Vanguard 5.51M $15.14M +8.5%
Geode Capital Management 2.96M $8.15M +4.9%
NTRS Northern Trust 2.1M $5.77M +2.7%
Cambridge Investment Research Advisors 1.65M $4.52M -10.4%
GAM General American Investors 1.64M $4.5M +63.5%
Charles Schwab Investment Management 1.4M $3.86M +4.7%
Susquehanna International 1.29M $3.56M +31.3%
Largest transactions
Shares Bought/sold Change
Viking Global Investors 0 -8.8M EXIT
STT State Street 22.29M +3.73M +20.1%
Two Sigma Investments 0 -1.92M EXIT
Millennium Management 0 -1.88M EXIT
tru Independence 1.01M +1.01M NEW
BLK Blackrock 13.18M +948.86K +7.8%
GAM General American Investors 1.64M +635.19K +63.5%
Commonwealth Equity Services 571.12K +571.12K NEW
Two Sigma Advisers 22.5K -462.5K -95.4%
Vanguard 5.51M +433.16K +8.5%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abrogating, accuracy, Africa, AgreementSM, alia, amalgamation, Ankura, Area, AstraZeneca, ATM, baseline, BCF, BCPIA, Biden, binding, biodefense, Biomedical, BioNTech, Braga, brand, Britain, broaden, BV, CDMO, circulation, client, collateral, coping, copy, COVID, CureVac, Damian, deadly, dedicated, deep, deployment, difficulty, disputed, dissipate, EC, ECDRP, EEA, encourage, explanatory, feature, footprint, formidable, Gag, globe, Great, hamper, hearing, hundred, HVB, Iceland, ideal, IIa, importantly, inadvertent, infiltration, innate, InVentiv, IRAP, Ireland, isolated, Johnson, leadership, lesser, Liechstenstein, load, longevity, Majesty, Medicago, MHRA, Minister, Minster, morphologically, mutated, necessitated, Northern, Norway, Novavax, nucleotide, obesity, obligor, opponent, Pacific, pandemic, paragraph, particulate, PDUFA, precautionary, Preceptive, prefusion, prepaid, prepayment, prime, prioritize, procurement, PRs, pseudoprogression, pursuit, Queen, reactive, readily, reallocate, receptor, recession, rectification, redacted, refinanced, relaxed, remediation, reperfoming, reperforming, repetitive, Resilience, resurgence, RNA, route, running, satisfactory, SE, shelf, shrinkage, SIF, signatory, skill, SNO, Sorbonne, specialist, Speed, spike, spontaneously, spread, subsided, suggesting, symptomatic, Therapure, today, topline, transmissibility, transmit, Trust, Twinrix, UK, unadjuvanted, Universit, Universite, unprecedented, unrealized, unreasonably, unredacted, unregistered, Valneva, variant, verified, vouching, Warp, worsening
Removed: Adam, aseptic, billion, brain, Buckley, Canaccord, cap, capped, comparative, content, deciding, display, dissolved, distribute, epithelial, exemption, filling, Florida, Genuity, geometric, immunologic, index, induced, inInternal, leveraging, LIBOR, manager, membrane, Miami, obliging, OPKO, outbound, package, percent, periodically, pool, preclinical, presidential, purification, reclassified, recommended, remeasured, reorganization, repurchased, resigned, secondary, statuary, synthetically, ticker, traditional, upstream, USA